Primary Systemic Therapy in Breast Cancer: Past Lessons and New Approaches

REFERENCES

• Wolmark N., Wang J., Mamounas E. P., Bryant J., Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001; 30: 96–102
   PubMedGoogle Scholar
• Rastogi P., Anderson S. J., Bear H. D., et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008; 26(5)778–785
   PubMed Web of Science ®Google Scholar
• van der Hage J. A., van de Velde C. J. H., Julien J-P., Tubiana-Hulin M., Vandervelden C., Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol 2001; 19(22)4224–4237
   PubMed Web of Science ®Google Scholar
• Bear H. D., Anderson S., Smith R. E., et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006; 24(13)2019–2027
   PubMed Web of Science ®Google Scholar
• von Minckwitz G., Raab G., Caputo A., et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 2005; 23(12)2676–2685
   PubMed Web of Science ®Google Scholar
• Symmans W. F., Peintinger F., Hatzis C., et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007; 25(28)4414–4422
   PubMed Web of Science ®Google Scholar
• Hutcheon A. W., Heys S. D., Sarkar T. K. Neoadjuvant docetaxel in locally advanced breast cancer. Breast Cancer Res Treat 2003; 79(Suppl 1)S19–S24
   PubMedGoogle Scholar
• von Minckwitz G., Kuemmel S., Du Bois A., et al. Individualized treatment strategies according to in vivo—chemosensitivity assessed by response after 2 cycles of neoadjuvant chemotherapy. Final results of the Gepartrio study of the German Breast Group. Breast Cancer Res Treat 2006
   PubMedGoogle Scholar
• Smith I. C., Heys S. D., Hutcheon A. W., et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002; 20(6)1456–1466
   PubMed Web of Science ®Google Scholar
• von Minckwitz G., Costa S. D., Raab G., et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study. J Clin Oncol 2001; 19(15)3506–3515
   PubMed Web of Science ®Google Scholar
• Henderson I. C., Berry D. A., Demetri G. D., et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21(6)976–983
   PubMed Web of Science ®Google Scholar
• Mamounas E. P., Bryant J., Lembersky B., et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005; 23(16)3686–3696
   PubMed Web of Science ®Google Scholar
• Bonnefoi H. “Small” randomised neo-adjuvant chemotherapy trials in breast cancer reporting on pathological response: more harm than good?. Ann Oncol 2005; 16(9)1407–1410
   PubMed Web of Science ®Google Scholar
• Paik S. Importance of obtaining preoperative research biopsies. Preoperative Therapy in Invasive Breast Cancer: Reviewing the State of the Science and Exploring New Research Directions. 2007, http://ctep.cancer.gov/bcmeeting
   Google Scholar
• Perou C. M., Sorlie T., Eisen M. B., et al. Molecular portraits of human breast tumours. Nature 2000; 406(6797)747
   PubMed Web of Science ®Google Scholar
• Rouzier R., Perou C. M., Symmans W. F., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11(16)5678–5685
   PubMed Web of Science ®Google Scholar
• Gianni L., Zambetti M., Clark K., et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005; 23(29)7265–7277
   PubMed Web of Science ®Google Scholar
• Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351(27)2817–2826
   PubMed Web of Science ®Google Scholar
• Paik S., Tang G., Shak S., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24(23)3726–3734
   PubMed Web of Science ®Google Scholar
• Buzdar A. U., Ibrahim N. K., Francis D., et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23(16)3676–3685
   PubMed Web of Science ®Google Scholar
• Slamon D. J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344(11)783–792
   PubMed Web of Science ®Google Scholar
• Coudert B. P., Largillier R., Arnould L., et al. Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2 overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial. J Clin Oncol 2007; 25(19)2678–2684
   PubMed Web of Science ®Google Scholar
• Garber J. E., Richardson A., Harris L., et al. Neo-adjuvant cisplatin (CDDP) in triple-negative breast cancer (BC). Breast Cancer Res Treat 2006; 100(Supp. 1)S19
   Google Scholar
• Hess K. R., Anderson K., Symmans W. F., et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006; 24(26)4236–4244
   PubMed Web of Science ®Google Scholar
• Chang J. C., Wooten E. C., Tsimelzon A., et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. The Lancet 2003; 362(9381)362
   PubMed Web of Science ®Google Scholar
• Chang J. C., Wooten E. C., Tsimelzon A., et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 2005; 23(6)1169–1177
   PubMed Web of Science ®Google Scholar
• Thuerigen O, Schneeweiss A, Toedt G, et al. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J Clin Oncol 2006; 24(12)1839–1845
   PubMed Web of Science ®Google Scholar
• Bonnefoi H. P. A., Delorenzi M., Mauriac L., Campone M., Tubiana-Hulin M., Petit T., Rouanet P., Jassem J., Blot E., Becette V., Farmer P., André S., Acharya C. R., Mukherjee S., Cameron D., Bergh J., Nevins J. R., Iggo R. D. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol 2007; 8(12)1071–1078
   PubMed Web of Science ®Google Scholar
• Potti A., Dressman H. K., Bild A., et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006; 12(11)1294–1300
   PubMed Web of Science ®Google Scholar
• Mayer E. L., Miller K. D., Rugo H. S., et al. A pilot study of adjuvant bevacizumab after neoadjuvant chemotherapy for high-risk breast cancer. J Clin Oncol 2007; 25(18S), Abs 561
   Google Scholar